plasma-derived biologics

1 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

B Group Doubles Down on Biotech Amid 58% Decline; ADMA Shows Profitability Gains

B Group increases ADMA stake to 21.4% of AUM amid 58% stock decline, betting on 22% profit growth and 28% ASCENIV sales momentum.
ADMAbiotechfund investment